Archive for the ‘Treatment’ Category

AutismOne 2019 Chicago Conference in May – Dr. Brown Speaking

conf-2019

Register here:  https://autismone.ticketspice.com/autism-one-2019-conference

The most rewarding educational and networking experience you can have at any autism conference!  An exceptional value as you gather new hope, answers, help, and direction.

New to the autism diagnosis? Come hear the “Newly Diagnosed” track just for you!
Yearning to learn more? Hear the “Biomedical Research and Treatments” track!

This conference will help you answer and understand important concepts:

  • Recovery from autism is possible and children get better!
  • There are medical comorbidities of autism that, when treated, allow the child to enjoy improved learning and behavior.

On the autism journey a little while? Come hear the latest research and healing information!
Medical professional? Hear renowned researchers present the latest cutting-edge autism research.

Conference track highlights include:
  • Membrane Medicine track
  • PANDAS/PANS track (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome)
  • 4th Annual International HPV Vaccine Education Symposium
  • Focus for Health Advocacy Training track
  • Chiropractic Pediatric Continuing Education Credit Program with Emphasis on Autism
  • Endocannabinoid Medicine track
  • ADHD (attention-deficit/hyperactivity disorder) track
  • Culinary Day: Culinary Day on a Budget
  • And a special surprise panel that illuminates the bigger picture that affects your family’s world

The AutismOne 2019 Conference will be held May 22-26, 2019, at the Loews Chicago O’Hare Hotel in Rosemont, IL.

“AutismOne always has the cutting-edge information years ahead of any other autism conference. You hear it first at AutismOne.” ~Janet Cakir, PhD

CONFERENCE SCHEDULE-AT-A-GLANCE

WEDNESDAY, MAY 22, LECTURES:
1:30PM-6:00PM

THURSDAY, MAY 23, LECTURES, MOVIES, PANELS:
8:30AM-10:15PM

FRIDAY, MAY 24, LECTURES AND PANELS:
8:30AM-5:45PM

SATURDAY, MAY 25, LECTURES AND PANELS:
8:30AM-7:00PM

SUNDAY, MAY 26, LECTURES:
8:45AM-1:30PM

See list of speakers:  https://autismoneconference.com/conference_speakers.html  Erica Linn, MSN & Dr. Greg Brown MD from Serenity Health in Wisconsin will be speakers at the conference.  Dr. Brown treats children and adults with Lyme/MSIDS as well as PANS/PANDAS.  He’s stated that up to 80% of his autistic and PANS/PANDAS patients are infected with Lyme/MSIDS.

For more on that connection:  https://madisonarealymesupportgroup.com/2017/10/01/panspandas-steroids-autoimmune-disease-lymemsids-the-need-for-medical-collaboration/

https://madisonarealymesupportgroup.com/2017/10/08/misdiagnosed-how-children-with-treatable-medical-issues-are-mistakenly-labeled-as-mentally-ill/

https://madisonarealymesupportgroup.com/2017/06/30/child-with-lymemsidspans-told-by-doctors-she-made-it-all-up/

https://madisonarealymesupportgroup.com/2017/10/09/today-is-panspandas-awareness-day/  Trifiletti officially diagnosed Carson with PANS, not PANDAS, due to the active co-infections found in his blood work: mycoplasma, the bacteria that causes pneumonia; coxsackie — the virus causing Hand, Foot and Mouth disease; streptococcus, the bacteria causing strep throat; bartonella and babesia — a bacteria and parasite related to Lyme disease; and yeast, Melissa Spears said.

Instead of attacking these infections, Carson’s antibodies were instead going after his brain.

https://madisonarealymesupportgroup.com/2018/03/14/dr-frid-children-lyme/

Innovative “Alternative” Therapies for Chronic Lyme Disease

https://restorativemedicine.org/wp-content/uploads/2017/01/4Holtorf_-Lyme-CFS.pdf  (Slides Found in link)

iu-7

Innovative “Alternative” Therapies for Chronic Lyme Disease

Kent Holtorf, M.D.

Holtorf Medical Group National Academy of Hypothyroidism Kholt@holtorfmed.com

 

 

Cochrane Review – Probiotics Reduce C-diff By 70% in High Risk Patients Taking Antibiotics

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006095.pub4/abstract

Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children

Abstract

Background

Antibiotics can disturb gastrointestinal microbiota which may lead to reduced resistance to pathogens such as Clostridium difficile (C. difficile). Probiotics are live microbial preparations that, when administered in adequate amounts, may confer a health benefit to the host, and are a potential C. difficile prevention strategy. Recent clinical practice guidelines do not recommend probiotic prophylaxis, even though probiotics have the highest quality evidence among cited prophylactic therapies.

Objectives

To assess the efficacy and safety of probiotics for preventing C.difficile‐associated diarrhea (CDAD) in adults and children.

Search methods

We searched PubMed, EMBASE, CENTRAL, and the Cochrane IBD Group Specialized Register from inception to 21 March 2017. Additionally, we conducted an extensive grey literature search.

Selection criteria

Randomized controlled (placebo, alternative prophylaxis, or no treatment control) trials investigating probiotics (any strain, any dose) for prevention of CDAD, or C. difficile infection were considered for inclusion.

Data collection and analysis

Two authors (independently and in duplicate) extracted data and assessed risk of bias. The primary outcome was the incidence of CDAD. Secondary outcomes included detection of C. difficile infection in stool, adverse events, antibiotic‐associated diarrhea (AAD) and length of hospital stay. Dichotomous outcomes (e.g. incidence of CDAD) were pooled using a random‐effects model to calculate the risk ratio (RR) and corresponding 95% confidence interval (95% CI). We calculated the number needed to treat for an additional beneficial outcome (NNTB) where appropriate. Continuous outcomes (e.g. length of hospital stay) were pooled using a random‐effects model to calculate the mean difference and corresponding 95% CI. Sensitivity analyses were conducted to explore the impact of missing data on efficacy and safety outcomes. For the sensitivity analyses, we assumed that the event rate for those participants in the control group who had missing data was the same as the event rate for those participants in the control group who were successfully followed. For the probiotic group, we calculated effects using the following assumed ratios of event rates in those with missing data in comparison to those successfully followed: 1.5:1, 2:1, 3:1, and 5:1. To explore possible explanations for heterogeneity, a priori subgroup analyses were conducted on probiotic species, dose, adult versus pediatric population, and risk of bias as well as a post hoc subgroup analysis on baseline risk of CDAD (low 0% to 2%; moderate 3% to 5%; high > 5%). The overall quality of the evidence supporting each outcome was independently assessed using the GRADE criteria.

Main results

Thirty‐nine studies (9955 participants) met the eligibility requirements for our review. Overall, 27 studies were rated as either high or unclear risk of bias. A complete case analysis (i.e. participants who completed the study) among trials investigating CDAD (31 trials, 8672 participants) suggests that probiotics reduce the risk of CDAD by 60%. The incidence of CDAD was 1.5% (70/4525) in the probiotic group compared to 4.0% (164/4147) in the placebo or no treatment control group (RR 0.40, 95% CI 0.30 to 0.52; GRADE = moderate). Twenty‐two of 31 trials had missing CDAD data ranging from 2% to 45%. Our complete case CDAD results proved robust to sensitivity analyses of plausible and worst‐plausible assumptions regarding missing outcome data and results were similar whether considering subgroups of trials in adults versus children, inpatients versus outpatients, different probiotic species, lower versus higher doses of probiotics, or studies at high versus low risk of bias. However, in a post hoc analysis, we did observe a subgroup effect with respect to baseline risk of developing CDAD. Trials with a baseline CDAD risk of 0% to 2% and 3% to 5% did not show any difference in risk but trials enrolling participants with a baseline risk of > 5% for developing CDAD demonstrated a large 70% risk reduction (interaction P value = 0.01). Among studies with a baseline risk > 5%, the incidence of CDAD in the probiotic group was 3.1% (43/1370) compared to 11.6% (126/1084) in the control group (13 trials, 2454 participants; RR 0.30, 95% CI 0.21 to 0.42; GRADE = moderate). With respect to detection of C. difficile in the stool pooled complete case results from 15 trials (1214 participants) did not show a reduction in infection rates. C. difficile infection was 15.5% (98/633) in the probiotics group compared to 17.0% (99/581) in the placebo or no treatment control group (RR 0.86, 95% CI 0.67 to 1.10; GRADE = moderate). Adverse events were assessed in 32 studies (8305 participants) and our pooled complete case analysis indicates probiotics reduce the risk of adverse events by 17% (RR 0.83, 95% CI 0.71 to 0.97; GRADE = very low). In both treatment and control groups the most common adverse events included abdominal cramping, nausea, fever, soft stools, flatulence, and taste disturbance.

Authors’ conclusions

Based on this systematic review and meta‐analysis of 31 randomized controlled trials including 8672 patients, moderate certainty evidence suggests that probiotics are effective for preventing CDAD (NNTB = 42 patients, 95% CI 32 to 58). Our post hoc subgroup analyses to explore heterogeneity indicated that probiotics are effective among trials with a CDAD baseline risk >5% (NNTB = 12; moderate certainty evidence), but not among trials with a baseline risk ≤5% (low to moderate certainty evidence). Although adverse effects were reported among 32 included trials, there were more adverse events among patients in the control groups. The short‐term use of probiotics appears to be safe and effective when used along with antibiotics in patients who are not immunocompromised or severely debilitated. Despite the need for further research, hospitalized patients, particularly those at high risk of CDAD, should be informed of the potential benefits and harms of probiotics.

 

What is Clostridium difficile‐associated diarrhea?

Antibiotics are among the most prescribed medications worldwide. Antibiotic treatment may disturb the balance of organisms that normally populate the gut. This can result in a range of symptoms, most notably, diarrhea. Clostridium difficile (C. difficile) is a particularly dangerous organism that may colonize the gut if the normal healthy balance has been disturbed. Clostridium difficile‐related disease varies from asymptomatic infection, diarrhea, colitis, and pseudo‐membranous colitis to toxic megacolon and death. The cost of treatment is expensive and the financial burden on the medical system is substantial.

What are probiotics?

Probiotics are live organisms (bacteria or yeast) thought to improve the balance of organisms that populate the gut, counteracting potential disturbances to the gut microbial balance that are associated with antibiotic use, and reducing the risk of colonization by pathogenic bacteria. Probiotics can be found in dietary supplements or yogurts and are becoming increasingly available as capsules sold in health food stores and supermarkets. As ‘functional food’ or ‘good bacteria’, probiotics have been suggested as a means of both preventing and treating C. difficile‐associated diarrhea (CDAD).

What did the researchers investigate?

The researchers investigated whether probiotics prevent CDAD in adults and children receiving antibiotic therapy and whether probiotics causes any harms (side effects). The researchers searched the medical literature extensively up to 21 March 2017.

What did the researchers find?

This review includes 39 randomized trials with a total of 9955 participants. Thirty‐one studies (8672 participants) assessed the effectiveness of probiotics for preventing CDAD among participants taking antibiotics. Our results suggest that when probiotics are given with antibiotics the risk of developing CDAD is reduced by 60% on average. Among trials enrolling participants at high risk of developing CDAD (> 5%), the potential benefit of probiotics is more pronounced with a 70% risk reduction on average. Side effects were assessed in 32 studies (8305 participants) and our results suggest that taking probiotics does not increase the risk of developing side effects. The most common side effects reported in these studies include abdominal cramping, nausea, fever, soft stools, flatulence, and taste disturbance. The short‐term use of probiotics appears to be safe and effective when used along with antibiotics in patients who are not immunocompromised or severely debilitated. Despite the need for further research, hospitalized patients, particularly those at high risk of CDAD, should be informed of the potential benefits and harms of probiotics.

Could Prescription Vegetables Be the Future of Healthcare?

https://www.medicalnewstoday.com/articles/324770.php?

Could prescription vegetables be the future of healthcare?

Published
The authors of a new study conclude that healthful food prescriptions in Medicare and Medicaid would be more cost-effective after 5 years than preventive drug treatments.
Father and daughter shopping

As the cost of healthcare rises, could prescription vegetables save money?

Medicare and Medicaid are the two largest healthcare programs in the United States.

Approximately 57 million people received coverage from Medicare plans in 2016, while Medicaid had about 66 million enrollees in 2018.

Medicare is the federal health insuranceprogram that supports certain groups of people, including those who are 65 years or older, those with permanent kidney failure, and some younger people with disabilities.

Medicaid is a federal and state program that helps people who have limited income and resources.

Medicare accounted for 15 percent of the federal budget in 2017. As the population ages and healthcare costs rise, experts estimate that healthcare spending will continue to grow. According to projections, Medicare spending will reach 18 percent by 2028.

Encouraging people to eat better

A team of researchers from Tufts University and Brigham and Women’s Hospital in Boston, MA analyzed the effects of healthful food prescriptions in Medicare and Medicaid. The study, which the journal PLOS Medicine published, found that offsetting the cost of healthful foods by 30 percent through health insurance would improve health and reduce costs.

According to the co-first author Dr. Dariush Mozaffarian, dean of the Friedman School of Nutrition Science and Policy at Tufts:

“Medicare and Medicaid are the two largest healthcare programs in the U.S., together covering one in three Americans and accounting for 1 in every 4 dollars in the entire federal budget.”

The researchers modeled two different scenarios that would play out if Medicare and Medicaidcovered 30 percent of healthful food purchases.

In both scenarios, these programs would cover 30 percent of fruit and vegetable purchases. However, in the second scenario, they would also cover 30 percent of purchases of whole grains, nuts, seafood, and plant oils.

The findings showed that the first scenario would prevent about 1.93 million cases of heart disease, while the second one would prevent close to 3.28 million cases of heart disease as well as 120,000 cases of diabetes.

The positive effect on diabetes is due to the role that whole grains, nuts, and seeds play in diabetes prevention.

“We found that encouraging people to eat healthy foods in Medicare and Medicaid — healthy food prescriptions — could be as or more cost-effective as other common interventions, such as preventative drug treatments for hypertension or high cholesterol,” says Yujin Lee, Ph.D., a postdoctoral fellow at the Friedman School and co-first author of the study.

Reducing the need for healthcare

Both scenario one and scenario two significantly reduced healthcare utilization, leading to savings of about $40 billion and $100 billion respectively. The total costs for subsidizing just fruits and vegetables were $122.6 billion, while it cost $210.4 billion to cover the broader range of healthful foods.

Comparing the net costs with savings and health benefits, both scenarios were highly cost-effective.

To conduct this study, the researchers used a validated micro-simulation model called CVD Predict that generated samples representative of the Medicare, Medicaid, and dual-eligible populations. To achieve this, they used data from recent National Health and Nutrition Examination Surveys (NHANES), published sources, and meta-analyses.

They then applied the two scenarios to each of the different samples and assessed their effect at 5-, 10-, and 20-year horizons and at a simulated lifetime horizon.

This research forms part of the Food Policy Review and Intervention Cost-Effectiveness (Food-PRICE) research initiative, which is a collaboration of international researchers who are working to improve the health of the U.S. population by identifying possible nutrition strategies and evaluating their cost-effectiveness.

These new findings support the concept of [the public initiative] Food is Medicine: That innovative programs to encourage and reimburse healthy eating can and should be integrated into the healthcare system.”

Dr. Dariush Mozaffarian

The researchers believe that this study provides the best national assessment of the potential effects that these initiatives could have at the federal level, but they caution that these models cannot prove the health and cost effects of the incentives.

_________________

**Comment**

My main reason for posting this article is to demonstrate how important diet is to us.  It IS literally MEDICINE and not to be taken lightly.  These links shows how sugary drinks fed tumors in mice & may be implicated in cardiovascular disease:  http://science.sciencemag.org/content/363/6433/1345, and https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.037401

These articles reveal that when you eat is important as well.  This article shows that time restricted eating may prevent cancer:  https://www.eurekalert.org/pub_releases/2019-03/tes-tem032019.php.  The take away is we should eat when we are active – within an 8-hour window. Along the same lines, this study showed that eating later into the day was associated with higher BMI & fat mass, both of which lead toward disease:  https://www.abstractsonline.com/pp8/#!/5752/presentation/20950

Regarding medical insurance:

My now deceased holistic MD told me that he remembered the original intent of health insurance was only to bridge the gap from when farmers collected money from the sale of their crops to pay their medical bills. Now, insurance is so expensive people have to seriously cut back in other areas – such as budgeting for food.

In this article, you can read about alternatives to traditional health insurance:

You should consider these as typical insurance often won’t cover Lyme/MSIDS anyway. There are also much less expensive programs that actually can cover your treatment. Sometimes the only caveat to that is that you must be a member prior to your diagnosis – i.e. it isn’t a “preexisting condition.”
After going without insurance for a number of years due to cost we finally joined a “medical cost sharing program.” While it didn’t cover Lyme/MSIDS for us because it was a preexisting condition, it does cover many adjunctive therapies regular insurance won’t cover – provided your doctor writes a brief letter explaining why he/she feels it an appropriate treatment. We’ve had colonics, massages, laser therapy, and a whole host of treatment modalities that never in a million years would be covered by regular insurance.

Bioidentical Hormone Talk – Brookfield, WI April 17, 2019

Dr. Deb’s First Talk of 2019!
Wednesday, April 17th at MD Custom Rx in Brookfield, WI
If you want to learn more about Hormones & Bio-Identical Hormone Therapy, you’re in luck – Dr. Deb will be speaking at MD Custom Rx, in Brookfield, WI on April 17th! Come join us from 6:30pm to 8:00pm to listen and learn about BHRT! The cost is $10 per person, received as a customer credit the day of the event.
Call (262) 373-1050 to register!
An Update On Bio-Identical Hormone Therapy
Wednesday, April 17 | 6:30pm – 8:00pm
Are you coming to Dr. Deb’s talk!?
LOCATION
MD Custom Rx – 19035 W Capitol Dr. STE 105 Brookfield, WI (In the Sendiks Towne Center)

DATE AND TIME
04/17/19 6:30pm – 04/17/19 8:00pm

Call (262) 373-1050 to register! Spaces are limited! Cost is $10.00 per person – will receive a supplement credit the day of event!
I’ll be there!
Maybe
I can’t make it